# Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

> **NCT07454837** · PHASE2,PHASE3 · RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Hepatitis D

## Interventions

- **DRUG:** Brelovitug (BJT-778)
- **DRUG:** Bulevirtide

## Key facts

- **NCT ID:** NCT07454837
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-03-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454837, "Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07454837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*